Kyrgyzstan Market Entry Strategy for China Medical Device Manufacturers: Representative, Documentation and Pathway Choice

1. Key takeaways

For manufacturers from China entering the Kyrgyzstan market, three questions must be resolved in a fixed order: first, appoint an authorized representative of the manufacturer that is a resident of Kyrgyzstan (statutorily mandatory, and the party that bears responsibility); second, complete the localization of documents and the notarization and legalization chain (work is conducted in Russian, and the order of legalizations must not be reversed); third, make the pathway choice between the national track and the Union track (depending on the number of target markets and the frequency of product changes). The order must not be reversed — until the authorized representative is in place, neither of the other two can even begin.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1, Article 2: the authorized representative of the manufacturer must be a legal entity or individual entrepreneur that is a resident of the Kyrgyz Republic, acting under a power of attorney, representing the interests of the manufacturer and bearing responsibility.
2. Article 14 of Law No. 216: foreign products must have confirmation that they circulate as devices in the country of manufacture or in other countries, and must obtain a positive expert appraisal taking into account the potential risk level.
3. Article 15 of Law No. 216: registration certificates are issued without an expiry date.
4. Protocol amending the agreement of December 23, 2014, signed December 29, 2025: national-track applications extended to December 31, 2027, re-registration and changes to December 31, 2028.
5. Cabinet Resolution No. 450, June 29, 2026: the inspection procedure.
6. Draft amendments published in 2026 by the Ministry of Health of the Kyrgyz Republic: the simplified pathway for eight countries and the inspection report recognition mechanism (draft status).

3. Expert insights

Insight one: of the three questions, the first is a hard constraint and the other two are choices.

The residency requirement for the authorized representative is a statutory mandatory condition with no alternative; document localization and pathway selection leave room for optimization. At project launch, resources should therefore be tilted toward the first question — finding a reliable authorized representative is worth more than preparing a few extra documents.

Insight two: the relative disadvantage of Chinese manufacturers on eight-country approvals can be offset in other ways.

The simplified pathway recognizes approvals from the eight countries of the European Union, Australia, the United Kingdom, Canada, the United States, Switzerland, Norway and Japan; approvals from China’s NMPA are not among them. Most Chinese manufacturers must therefore follow the standard procedure (currently at most 50 calendar days). Two offsetting directions are available: first, pursue positive manufacturing inspection reports from Union member states (the draft would recognize confirmation by at least two member states); second, make the model list as complete as possible at first registration to reduce repeated registrations later.

Insight three: the size of the Kyrgyz market determines its strategic positioning.

Kyrgyzstan is a market of limited size with traditional and fragmented channels, but it carries two layers of added value: as a Union member state, the Union track makes it part of a multi-country footprint; and it has demand driven by government procurement and international assistance programs. We recommend positioning it within an overall Central Asia plus Union layout rather than evaluating it as a standalone market.

Insight four: Russian-language capability is a hidden threshold in this market.

Document submission, official communications, labels and instructions for use, and inspection cooperation are all conducted primarily in Russian. This is not a translation problem but a working-language problem. We recommend staffing the project team with people able to read Russian regulations and official correspondence directly, or relying on a professional organization with Russian working capability.

Insight five: the transition endpoints give real-world justification to the sequence of national track first, Union track later.

The underlying rules of technical files prepared under the national track share the same roots as the Union track (Article 2 of Cabinet Resolution No. 513 makes five cross-references). This means that evidence investments made now under the national track can be reused when migrating after 2028. For companies that need a certificate and revenue first, the route from the national track to the Union track is viable, but a migration plan should be prepared in parallel (see article 11 of this series).

4. Practical recommendations

First, make the selection of the authorized representative the first project step. We recommend screening against four criteria: dedicated regulatory staff, experience with similar products, capability to support import, surveillance and inspections, and operational and financial stability. The selection criterion is the capacity to bear responsibility, not the quotation.

Second, start document work and technical work in parallel. We recommend launching, alongside the preparation of the technical file, three external processes: obtaining the certificate of free sale, notarization and legalization of the power of attorney, and Russian translation (see article 20 of this series).

Third, decide the pathway with three questions. We recommend answering at the project kickoff: the number of target markets, the expected frequency of changes, and the existing stock of approvals. The combination of the three answers will usually give a clear direction.

Fourth, prepare fallback options for the reality of holding no eight-country approvals. We recommend: first, compiling existing manufacturing inspection reports from Union member states; second, submitting a complete model list at first registration; third, scheduling on the basis of the standard procedure of 50 calendar days plus 90 calendar days for inspection plus a buffer.

Fifth, place Kyrgyzstan within the regional layout as a whole. We recommend planning by market nature, grouping Union member states (eligible for the Union track) separately from non-member states (for example, Uzbekistan requires separate registration), avoiding the misjudgment that one registration covers the neighborhood (see article 40 of this series).

Sixth, build Russian-language working capability. We recommend designating in the project team an owner for Russian-language regulations and correspondence, or relying on a professional organization with that capability.

5. Verification checklist

• □ The authorized representative has been selected against the four criteria (dedicated regulatory staff, experience with similar products, cooperation capability, operational stability);
• □ Document work (certificate of free sale, notarization and legalization of the power of attorney, Russian translation) has been launched in parallel with technical work;
• □ The three-question pathway decision has been completed: number of target markets, expected change frequency, existing approval assets;
• □ Fallback options for holding no eight-country approvals are ready: compiled Union inspection reports, a complete model list, a full schedule (50 plus 90 calendar days plus a buffer);
• □ Kyrgyzstan has been placed within a regional layout grouped into Union member states and non-member states;
• □ The project team has Russian-language capability for regulations and correspondence;
• □ If the national track is chosen, a Union-track migration plan has been prepared in parallel, factoring in the change deadline of December 31, 2028.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system conformity support, post-market surveillance and vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations and has built stable local cooperation networks in Bishkek, Almaty, Tashkent and Moscow. Working in Chinese, Russian and English, we deliver actionable solutions for foreign manufacturers on the key issues commonly encountered in CIS markets, including authorized representative arrangements, notarization and legalization chains for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources; figures and timelines that cannot be verified are always marked as practical estimates and are never presented as legal requirements drawn from experience.

GRZAN provides registration and compliance support in this country for manufacturers, importers and authorized representatives. For project inquiries on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Regulatory Registration and Compliance Services for Medical Devices